Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hereditary Transthyretin Amyloidosis Market Growth Potential: How Will Market Size Shift Through 2030?
The market size for hereditary transthyretin amyloidosis has experienced robust growth in recent years. It is projected to expand from $1.49 billion in 2025 to $1.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. Historically, this expansion has been fueled by several factors, including heightened clinical recognition of ATTR amyloidosis, the accessibility of tafamidis therapy, the proliferation of specialized neurology and cardiology centers, enhancements in genetic testing for TTR mutations, and the growth of patient registry programs.
The hereditary transthyretin amyloidosis market is poised for robust expansion in the coming years. It is projected to attain a value of $2.28 billion in 2030, advancing at a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast period stems from the proliferation of next-generation gene therapies, increased investment in rare disease research, the rising embrace of precision medicine approaches, the escalating development of CRISPR-based treatments, and enhanced technologies for monitoring disease outcomes. Prominent trends expected in the forecast period feature the increasing adoption of gene silencing therapies, a growing reliance on RNAi-based treatments, a heightened focus on early cardiac and neurological diagnosis, the broadening of oral therapeutic options, and improved long-term disease management strategies.
Get A Free Sample Report With In-Depth Market Insights:
Hereditary Transthyretin Amyloidosis Market Development Factors: What’s Supporting Demand?
The increasing number of elderly individuals is projected to drive expansion within the hereditary transthyretin amyloidosis market in the future. The term “geriatric population” encompasses people aged 65 and above, who frequently need specialized medical attention and assistance as they age. This demographic is expanding because of longer life expectancies, a result of improvements in medical care and general living standards. Hereditary transthyretin amyloidosis (hATTR) has a substantial effect on the elderly, inducing progressive nerve damage and heart muscle disease, which contributes to higher rates of illness among older people. For example, data from January 2024, provided by the US-based nonprofit Population Reference Bureau, indicates that the United States’ population aged 65 and older is predicted to climb from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Consequently, the expanding elderly demographic is a key impetus for the hereditary transthyretin amyloidosis market’s development.
Hereditary Transthyretin Amyloidosis Market Segments: Where Is Growth Concentrated?
The hereditary transthyretin amyloidosis market covered in this report is segmented –
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Experimental Oral Therapies
2) By Subcutaneous Injection: Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Hereditary Transthyretin Amyloidosis Market Trends Powering Strategic Industry Growth
Leading companies in the hereditary transthyretin amyloidosis market are actively developing innovative treatments, such as RNAi therapeutics, aimed at targeting and diminishing the generation of transthyretin (TTR) protein. These RNAi therapeutics constitute a class of medications that utilize RNA interference technology to silence specific genes, thereby reducing the synthesis of disease-causing proteins. For example, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) for the treatment of transthyretin amyloidosis with cardiomyopathy. This submission emphasizes its inventive RNAi therapeutic strategy, specifically engineered to target and lower the transthyretin (TTR) protein, a crucial factor in the disease’s progression. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to conventional intravenous treatments, establishing it as a potentially transformative alternative for individuals suffering from this severe condition.
Hereditary Transthyretin Amyloidosis Market Key Participants And Competitive Landscape
Major companies operating in the hereditary transthyretin amyloidosis market are Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.
View The Full Hereditary Transthyretin Amyloidosis Market Report:
Hereditary Transthyretin Amyloidosis Market Geographic Spread And Regional Opportunities
North America was the largest region in the hereditary transthyretin amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
